Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon distancing Provigil from Plavix

Executive Summary

Cephalon believes that its settlements with four generic manufacturers over patents for the excessive sleepiness therapy Provigil are not comparable to Bristol-Myers Squibb and Sanofi-Aventis' recently rejected settlement with Apotex over Plavix generics. When asked by "The Pink Sheet" whether FTC granted antitrust clearance to the deals, firm responds: "Our case is unrelated to the Bristol-Myers case. Cephalon is not subject to a consent decree that would require FTC approval of settlements. Similarities end at the fact that we both have made settlements with generic companies." The Provigil agreements are subject to antitrust clearance and FTC has expressed concern about the deals (1"The Pink Sheet" May 1, 2006, p. 10)...
Advertisement

Related Content

Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition
Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition
Advertisement
UsernamePublicRestriction

Register

PS047464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel